Liensinine perchlorate
Based on 21 publication(s) in Google Scholar
Liensinine perchlorate is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine perchlorate suppresses autophagy and apoptosis, clears Aβ, and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine perchlorate activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine perchlorate exerts anti-tumor effects through ROS-mediated inhibition of the JAK2/STAT3 signaling pathway. Liensinine perchlorate can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke.
For research use only. We do not sell to patients.
- Purity: 99.67%
- CAS No.: 2385-63-9
- Formula: C37H42N2O6.xHClO4
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) Liensinine perchlorate
More- Signal Transduct Target Ther. 2025 Dec 17;10(1):413. [Abstract]
- Redox Biol. 2025 Oct:86:103793. [Abstract]
- Cell Death Dis. 2023 Sep 30;14(9):645. [Abstract]
- Int J Biol Sci. 2022 Aug 8;18(13):5168-5184. [Abstract]
- Anim Nutr. 2026 Feb 6:25:160-174. [Abstract]
- Chin Med. 2026 Jan 24;21(1):51. [Abstract]
- J Ethnopharmacol. 2024 Nov 15:334:118576. [Abstract]
- Life Sci. 2023 Jun 1:322:121653. [Abstract]
- Int J Mol Sci. 2025 May 10;26(10):4566. [Abstract]
- Molecules. 2026 Mar 12;31(6):947. [Abstract]
- J Mol Med (Berl). 2025 Dec 26;104(1):13. [Abstract]
- J Biol Chem. 2024 Aug;300(8):107542. [Abstract]
- Adipocyte. 2022 Dec;11(1):202-212. [Abstract]
- Tissue Cell. 2026 Jun 12:103:103696. [Abstract]
- Genes Nutr. 2025 Dec 24;20(1):29. [Abstract]
- J Int Med Res. 2026 Feb;54(2):3000605261419604. [Abstract]
- Lett Drug Des Discov. 2025 Dec 2.
- SSRN. 2023 Apr 18.
- Research Square Print. 2023 Mar 24.
- J Oncol. 2022 Jul 1:2022:1533779. [Abstract]
- Oxid Med Cell Longev. 2022 Jan 25:2022:8245614. [Abstract]
-
Cell Proliferation/Viability Assay
-
WB
-
Flow Cytometry
-
Cell Imaging/Staining
-
RT-PCR
All VEGFR Isoforms
More
Biological Activity
IC50: apoptosis[1]
Liensinine (5-80 μM; 24 h) perchlorate reduces the viability of SaOS-2, MG-63, 143B and U-2OS osteosarcoma cells in a dose-dependent manner, but has no effect on the viability of hFOB 1.19 normal osteoblasts[1].
Liensinine (40-80 μM; 24 h) perchlorate inhibits the proliferation and colony-forming ability of SaOS-2 and 143B osteosarcoma cells, induces apoptosis, and causes G0/G1 cell cycle arrest in a dose-dependent manner[1].
Liensinine (40-80 μM; 24 h) perchlorate increases intracellular ROS production in SaOS-2 and 143B osteosarcoma cells in a dose-dependent manner, but does not affect ROS levels in hFOB 1.19 normal osteoblasts[1].
Liensinine (40-80 μM; 24 h) perchlorate disrupts the GSH/GSSG redox balance in SaOS-2 and 143B osteosarcoma cells in a dose-dependent manner by decreasing GSH levels, increasing GSSG levels, and elevating the GSSG/GSH ratio[1].
Liensinine (40-80 μM; 24 h) perchlorate induces the loss of mitochondrial membrane potential in SaOS-2 and 143B osteosarcoma cells in a dose-dependent manner[1].
Liensinine (40-80 μM; 24 h) perchlorate dose-dependently regulates the expression of apoptosis- and cell cycle-related proteins in SaOS-2 and 143B osteosarcoma cells in vitro, and inhibits the activation of the JAK2/STAT3 pathway, but exerts no effect on the aforementioned proteins in hFOB 1.19 normal osteoblasts[1].
Liensinine (20 μM; 24 h) perchlorate enhances cell viability, reduces apoptosis and cytotoxicity, and inhibits autophagy in an in vitro oxygen-glucose deprivation/reoxygenation ischemia-reperfusion model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Liensinine (20 mg/kg; i.p.; once daily for 16 consecutive days) perchlorate significantly inhibits orthotopic HCC tumor progression in male C57BL/6 mice, induces tumor metabolic reprogramming, reduces tumor vascular density, regulates macrophage polarization, and downregulates PD-L1 expression[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2385-63-9
-
Appearance Solid
-
Formula C37H42N2O6.xHClO4
-
Color White to off-white
-
SMILES
OC1=CC=C(C[C@H]2N(C)CCC3=C2C=C(OC)C(OC)=C3)C=C1OC4=CC5=C(C=C4OC)CCN(C)[C@@H]5CC6=CC=C(O)C=C6.[x HClO4]
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (21)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Disruption of heme homeostasis by nuclear receptor Nur77 induces pyroptosis through granzyme B-dependent GSDMC cleavage. [Abstract]2025 Dec 17;10(1):413. PMID: 41407678 -
Redox Biol
Arylsulfatase K attenuates airway epithelial cell senescence in COPD by regulating parkin-mediated mitophagy. [Abstract]2025 Oct:86:103793. PMID: 40763656
Liensinine perchlorate purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Oct:86:103793. [Abstract]
The viability of HBE cells treated with different concentration of Liensinine (LIE) (10, 20, 40, 60, 80 μM) measured by CCK8 assay.
Liensinine perchlorate purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Oct:86:103793. [Abstract]
Liensinine (LIE) (40 μM) treatment effectively suppressed autophagy by Western blot.
Liensinine perchlorate purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Oct:86:103793. [Abstract]
Liensinine (LIE) (40 μM) improved mitochondrial damage induced by ARSK knockdown, as evidenced by the reductions in intracellular and mitochondrial ROS levels.
Liensinine perchlorate purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Oct:86:103793. [Abstract]
SA-β-gal staining results demonstrated that Liensinine (LIE) (40 μM) treatment obviously decreased the percentage of positive cells.
Liensinine perchlorate purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Oct:86:103793. [Abstract]
The expressions of IL-6, IL-8 and IL-1β were both relived in HBE cells by Liensinine (LIE) (40 μM).
-
Cell Death Dis
Crotonylated BEX2 interacts with NDP52 and enhances mitophagy to modulate chemotherapeutic agent-induced apoptosis in non-small-cell lung cancer cells. [Abstract]2023 Sep 30;14(9):645. PMID: 37777549 -
Int J Biol Sci
Tubule-mitophagic secretion of SerpinG1 reprograms macrophages to instruct anti-septic acute kidney injury efficacy of high-dose ascorbate mediated by NRF2 transactivation. [Abstract]2022 Aug 8;18(13):5168-5184. PMID: 35982894 -
Anim Nutr
Caffeic acid phenethyl ester ameliorates high-fat diet-induced muscle textural deterioration in grass carp (Ctenopharyngodon idellus) by modulating adipose-muscle crosstalk via myostatin-taz signaling. [Abstract]2026 Feb 6:25:160-174. PMID: 41938616 -
Chin Med
Targeting G-protein-coupled receptors and gut microbiota: Ge-Lian Qi-Shen decoction elevates GLP-1 to combat non-alcoholic fatty liver disease. [Abstract]2026 Jan 24;21(1):51. PMID: 41580820 -
J Ethnopharmacol
Integrating UHPLC-Q-TOF-MS/MS, network pharmacology, bioinformatics and experimental validation to uncover the anti-cancer mechanisms of TiaoPi AnChang decoction in colorectal cancer. [Abstract]2024 Nov 15:334:118576. PMID: 39002822 -
Life Sci
Auto- and paracrine rewiring of NIX-mediated mitophagy by insulin-like growth factor-binding protein 7 in septic AKI escalates inflammation-coupling tubular damage. [Abstract]2023 Jun 1:322:121653. PMID: 37011875 -
Int J Mol Sci
Liensinine Prevents Acute Myocardial Ischemic Injury via Inhibiting the Inflammation Response Mediated by the Wnt/β-Catenin Signaling Pathway. [Abstract]2025 May 10;26(10):4566. PMID: 40429711 -
Molecules
Molecular Mechanisms Underlying the Anti-Tumor Activity of Lotus-Derived Alkaloids in Breast Cancer. [Abstract]2026 Mar 12;31(6):947. PMID: 41900047 -
J Mol Med (Berl)
Liensinine can improve vascular remodeling in hypertension through the ferroptosis-related TLR4 inflammatory pathway. [Abstract]2025 Dec 26;104(1):13. PMID: 41452356 -
J Biol Chem
Activation of Nemo-like Kinase in Diamond Blackfan Anemia suppresses early erythropoiesis by preventing mitochondrial biogenesis. [Abstract]2024 Aug;300(8):107542. PMID: 38992436 -
Adipocyte
The combination of nuclear receptor NR1D1 and ULK1 promotes mitophagy in adipocytes to ameliorate obesity. [Abstract]2022 Dec;11(1):202-212. PMID: 35410572 -
Tissue Cell
Liensinine induces autophagy and apoptosis in hepatocellular carcinoma via reactive oxygen species-mediated inhibition of the PI3K/AKT/mTOR pathway. [Abstract]2026 Jun 12:103:103696. PMID: 42314534 -
Genes Nutr
Liensinine alleviates type 2 diabetes mellitus through modulating the pancreatic β cell function and gut microbiota. [Abstract]2025 Dec 24;20(1):29. PMID: 41444518 -
J Int Med Res
RNA sequencing-based evaluation of the mechanisms underlying the liensinine-mediated inhibition of hypopharyngeal cancer proliferation. [Abstract]2026 Feb;54(2):3000605261419604. PMID: 41698653 -
-
-
-
J Oncol
2022 Jul 1:2022:1533779. PMID: 35813859 -
Oxid Med Cell Longev
Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway. [Abstract]2022 Jan 25:2022:8245614. PMID: 35116094
Solvent & Solubility
DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Jia F, et al. Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway. Oxid Med Cell Longev. 2022;2022:8245614. Published 2022 Jan 25. [Content Brief]
[2]. Zhang W, et al. Liensinine pretreatment reduces inflammation, oxidative stress, apoptosis, and autophagy to alleviate sepsis acute kidney injury. Int Immunopharmacol. 2023;122:110563. [Content Brief]
[3]. Qiao W, et al. Liensinine ameliorates ischemia-reperfusion-induced brain injury by inhibiting autophagy via PI3K/AKT signaling. Funct Integr Genomics. 2023;23(2):140. Published 2023 Apr 28. [Content Brief]
[4]. Wu MC, et al. Liensinine and neferine exert neuroprotective effects via the autophagy pathway in transgenic Caenorhabditis elegans. BMC Complement Med Ther. 2023;23(1):386. Published 2023 Oct 27. [Content Brief]
[5]. Liu J, et al. Liensinine reshapes the immune microenvironment and enhances immunotherapy by reprogramming metabolism through the AMPK-HIF-1α axis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2025;44(1):208. Published 2025 Jul 15. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)